Ascletis Showcases Obesity Treatment Innovations at ADA 2026 Scientific Sessions
Ascletis Pharma Inc. presented its latest research on obesity treatments at the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans. The company highlighted three key studies focusing on its differentiated portfolio, which includes small-molecule candidates and peptide therapeutics. The studies showcased the potential of ASC39, a potent oral amylin receptor agonist, ASC30, an oral GLP-1 receptor agonist, and ASC37, a GLP-1R/GIPR/GCGR triple agonist peptide. ASC39 demonstrated significant weight reduction in a diet-induced obesity rat model, while ASC30 showed promising results in a Phase II study with dose-dependent weight loss and favorable safety profiles. ASC37, developed using Ascletis' proprietary technology, exhibited enhanced oral bioavailability and extended half-life, indicating strong potential for clinical development in obesity and metabolic diseases. 
